The interim data from Pfizer (PFE) indicated no serious safety concerns, but the data covers a relatively short time period and safety issues could emerge as the company follows trial participants for a longer time. Which is why the U.S. Food & Drug Administration wants to see more data from a longer time period before […]
To subscribe to JAM you need to fill in some details below including, ahem, some info on how you'll pay us. A subscription is $199 (although if you're subscribing with one of our special offers it will be lower) for a year for ongoing and continuing access to the site. And we'll throw in the first week free! If you change your mind during that first week, just cancel your subscription from your profile page, and you won't be billed anything.
